Lemaitre Vascular ( (LMAT) ) has released its Q2 earnings. Here is a breakdown of the information Lemaitre Vascular presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
LeMaitre Vascular, Inc., a company specializing in vascular devices, implants, and services, operates within the medical device industry, focusing on solutions for peripheral vascular disease.
In its Q2 2025 financial report, LeMaitre Vascular announced a 15% increase in sales, reaching $64.2 million, alongside a 16% rise in earnings per diluted share to $0.60. The company also declared a quarterly dividend of $0.20 per share and provided updated guidance for the year.
Key drivers of the company’s growth included a 27% increase in catheter sales and a 19% rise in graft sales. Geographically, the EMEA region saw a 23% sales increase, while both the Americas and APAC regions experienced 12% growth. The gross margin improved to 70.0%, attributed to higher selling prices and manufacturing efficiencies. Operating income rose by 12% to $16.1 million, reflecting the company’s robust performance.
Looking ahead, LeMaitre Vascular’s management has increased its guidance for 2025, anticipating continued growth in both sales and profits. The company remains optimistic about its strategic initiatives and market expansion plans, aiming to sustain its upward trajectory in the coming quarters.